The conservative and interventional treatment of the complications of liver cirrhosis - Part 2 of a series on liver cirrhosis;Konservative und interventionelle therapie der komplikationen bei leberzirrhose: Teil 2 der serie zur leberzirrhose

Deutsches Arzteblatt International

Volumn 110, Issue 8, 2013, Pages 126-132+8

  Sauerbruch, Tilman ^a   Appenrodt, Beate ^b   Schmitz, Volker ^c   Spengler, Ulrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c St Marienwörth Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LOOP DIURETIC AGENT; SPIRONOLACTONE; TERLIPRESSIN;

ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLEEDING; BRAIN DISEASE; CONSERVATIVE TREATMENT; ENDOSCOPY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; INFECTION; INTERVENTION STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MULTIPLE ORGAN FAILURE; TREATMENT CONTRAINDICATION; COMPLICATION; HEPATIC ENCEPHALOPATHY; HYPERTENSION, PORTAL; LIVER NEOPLASMS;

HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84906329041     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Schepke M, Kleber G, Nürnberg D, et al.: German Study Group for the Primary Prophylaxis of Variceal Bleeding. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40: 65-72.
2. de Franchis R, Baveno V Faculty: Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Heptol 2010; 53: 762-8.
3. Merkel C, Marin R, Angeli P, et al.: Gruppo Triveneto per l'ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476-84.
4. D'Amico G, Criscuoli V, Fili D, Mocciaro F, Pagliaro L: Meta-analysis of trials for variceal bleeding. Hepatology 2002; 36(4 Pt 1): 1023-4; author's reply 1024-5.
5. García-Pagán JC, Caca K, Bureau C, et al.: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-9.
6. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al.: Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34: 509-518.
7. Funakoshi N, Ségalas-Largey F, Duny Y, et al.: Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010; 16: 5982-92.
8. Ding SH, Liu J, Wang JP: Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis. World J Gastroenterol 2009; 15: 2151-5.
9. Zheng M, Chen Y, Bai J, et al.: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophy laxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol 2008; 42: 507-16.
10. Gerbes AL, Gülberg V, Sauerbruch T, et al.: German S 3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome". Z Gastroenterol 2011; 49: 749-79.
11. Rössle M, Ochs A, Gülberg V, et al.: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-7.
12. Salerno F, Merli M, Riggio O, et al.: Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-35.
13. Salerno F, Cammà C, Enea M, Rössle M, Wong F: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-34.
14. Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-84.
15. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D: HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204-13.
16. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
17. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
18. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
19. Cholongitas E, Marelli L, Shusang V, et al.: A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12: 1049-61.
20. Häussinger D, Schliess F: Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
21. Zhan T, Stremmel W: The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int 2012; 109(10): 180-7.
22. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
23. Sharma BC, Sharma P, Agrawal A, Sarin SK: Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-91.
24. Bass NM, Mullen KD, Sanyal A, et al.: Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
25. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC: Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011; 11: CD008716.
26. Sauerbruch T, Wotzka R, Köpcke W, et al.: Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988; 319: 8-15.
27. Niederau C: Epidemiologie der Leberzirrhose. Hepatitis & More 2011; 1: 11-14.
28. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR: Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-35.
29. Mishra SR, Sharma BC, Kumar A, Sarin SK: Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011; 54: 1161-7.
30. Augustin S, Altamirano J, González A, et al.: Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol 2011; 106: 1787-95.
31. Arvaniti V, D'Amico G, Fede G, et al.: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56, 1256.e1-5.
32. Angermayr B, Cejna M, Koenig F, et al.: Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38: 1043-50.
33. Gines P, Quintero E, Arroyo V, et al.: Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
34. Sola-Vera J, Miñana J, Ricart E: Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53.
35. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
36. Gerbes AL, Huber E, Gülberg V: Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137: 1179; author reply 1179-81.
37. Brensing KA, Textor J, Perz J, et al.: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95.
38. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
39. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
40. Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
41. Sangro B, Carpanese L, Cianni R, et al.: European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-78. doi: 10.1002/hep.24451.
42. Butterworth RF: Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011; 53: 1372-6.
43. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
44. Bajaj JS: Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.
45. Prakash R, Mullen KD: Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.
46. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK: Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-16.
47. Bajaj JS, Heuman DM, Wade JB, et al.: Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487.
48. Neff GW, Jones M, Broda T, et al.: Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 2012; 46: 168-71.
49. Caldwell C, Werdiger N, Jakab S, et al.: Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transpl 2010; 16: 818 -26.